CERO earnings analysis
What we found in CERO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q does not provide revenue, margin, EPS, cash-flow, balance-sheet, or segment results, so operating performance cannot be assessed from the available filing text. The key developments are continued reliance on convertible financing, including a $2,235,200 maximum facility at 10% interest, and approximately 844,400,000 shares issuable upon conversion of outstanding notes. Sentiment is bearish because disclosure controls remain ineffective, remediation is not feasible without additional funding, and the company faces significant dilution and liquidity risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $2.24M financing facility expanded
- The company expanded its SRX Global convertible financing to a maximum loan amount of $2,235,200, including an additional $150,000 funded on August 11, 2026. The note bears interest at 10% and matures on May 28, 2027.
- Financing capacity remains available
- As of August 14, 2026, the company reported 71,630,992 common shares outstanding and approximately 844,400,000 common shares issuable upon conversion of convertible notes, providing a precise view of its potential equity financing capacity.
- Remediation tied to new funding
- The company stated that it had no viable remediation plan in the foreseeable future because of limited working capital in 2025 and 2024 and during the six months ended June 30, 2026. Remediation is contingent on receiving additional funding and expanding accounting staff.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weaknesses remain unremediated
- Disclosure controls were deemed ineffective as of June 30, 2026 because the company lacked multiple levels of management review and adequate segregation of duties. Management stated it could not implement a remediation plan in the foreseeable future due to limited working capital in 2025, 2024, and the six months ended June 30, 2026.
- Highly dilutive convertible debt
- The August 2026 Note is convertible at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the 20 days before conversion. The filing also identifies approximately 844,400,000 common shares issuable upon conversion of outstanding convertible notes, creating substantial dilution risk.
- Funding and maturity risk
- The August 2026 Note carries 10% interest and matures on May 28, 2027, while the company reported that it needs financing to fund research and development, clinical trials, and other operations. This combination indicates continuing liquidity and refinancing risk.
- Healthcare policy uncertainty
- The filing identifies potential healthcare reimbursement headwinds, including estimated $1 trillion in reduced federal Medicaid spending from 2025 through 2034 under the OBBBA. Lower insured-patient enrollment or reimbursement levels could adversely affect future revenue and commercial prospects if products are approved.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the extracted 10-Q. The filing instead discusses financing, liquidity constraints, and the need for additional funding.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- CERO Therapeutics reported no revenue for Q1 2026, with a notable net loss of $5.89 million and a diluted EPS of -0.20. Operating expenses remained high at approximately $4.85 million, primarily driven by R&D and G&A…
- 10-K · April 30, 2026
- CERO Therapeutics Holdings, Inc. provides an update on its financial performance and operational strategy through its 10-K filing for the fiscal year ended December 31, 2025. The company's lead cell therapy candidate,…
- 10-K · April 15, 2026
- CERo is an early-stage cell therapy company focused on its lead engineered CER-T candidate CER-1236 and novel cell-engineering platform. The 10-K discloses significant financing activity (multiple PIPE financings and a…
- 10-Q · May 15, 2025
- CERo reported no revenue and continued to operate at a loss as it ramps R&D spending. For the quarter ended March 31, 2025 the company recorded a net loss of $5,105,931 (net loss attributable to common shareholders…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CERO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever